Clinical Trials Browser

INDUSTRY × sacituzumab govitecan × 90 days × Clear all

NCT04527991 2026-06-02

TROPiCS-04

Phase 3 Completed

711 enrolled 25 charts

Locally Advanced or Metastatic Unresectable Urothelial Cancer

NCT04617522 2026-06-02

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

Phase 1 Recruiting

Neoplasm Metastasis, Liver Failure

NCT05633667 2026-06-01

VELOCITY-Lung

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06167317 2026-05-28

Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT07461454 2026-05-26

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT06801834 2026-05-20

EVOKE-SCLC-04

Phase 3 Recruiting

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT03337698 2026-05-12

Morpheus Lung

Phase 1/2 Terminated

314 enrolled 31 charts

Carcinoma, Non-Small-Cell Lung

NCT05089734 2026-05-07

EVOKE-01

Phase 3 Active not recruiting

603 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung

NCT05633654 2026-04-30

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT03964727 2026-04-28

TROPiCS-03

Phase 2 Active not recruiting

227 enrolled 31 charts

Neoplasm Metastasis

NCT05327530 2026-04-24

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07533123 2026-04-16

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT04794699 2026-04-09

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Phase 1 Active not recruiting

GenitourinaryThoracic

Urinary Bladder Neoplasms, Lung Neoplasms

NCT05382299 2026-04-06

ASCENT-03

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

Breast Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer